GR1803 plus anti-CD38 antibody for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new combination therapy (GR1803 plus an anti-CD38 monoclonal antibody) for people with multiple myeloma who have already tried lenalidomide and a proteasome inhibitor. It aims to see if the combination is safe and helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma and have already had at least one previous treatment that included lenalidomide (Revlimid) and a proteasome inhibitor (like bortezomib/Velcade).
- You are able to get around and take care of yourself (ECOG score of 0, 1, or 2).
- You have not had any treatment that targets BCMA before.
- You do not have an active infection or known allergies to the study drug ingredients.
- You do not have certain related conditions like plasma cell leukemia or myeloma that has spread to the brain.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SHR-3836 for patients with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if the drug is safe and how it works against the cancer.
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
This study tests CM336, a new type of immunotherapy drug, for patients with multiple myeloma (a blood cancer) that has come back or progressed after their first treatment. The trial aims to see if this drug can help control the disease in patients at high risk of relapse.
This trial tests CM336, a new medicine, in people with multiple myeloma that has returned (relapsed) or not responded (refractory) to standard treatments. It may help by trying a different approach when other key medicines have already been tried.
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
This trial tests a new drug called SHR-9539 for people with multiple myeloma, a type of blood cancer. The goal is to see if it is safe and how it affects the cancer.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.